-
Beyond the Rule of 5: Vastly Expanding Targetable Drugs
Bio-IT World | At the Drug Discovery Chemistry Virtual conference, researchers from industry and academia provide a glimpse into the expanse of pharmaceuticals available beyond Lipinski’s Rule of 5, an endeavor that will hopefully enable the development of much more specific agents with vastly expanded targetable options.
Sep 8, 2020
-
Computational Tool Could Improve Clinical Success Rate Of Drugs
Bio-IT World A newly developed translatable components regression (TransComp-R) model, developed by researchers from Purdue University and the Massachusetts Institute of Technology (MIT), recently identified an overlooked biological mechanism possibly responsible for resistance to the drug infliximab commonly prescribed to patients with inflammatory bowel disease (IBD).
Sep 8, 2020
-
Mouse Models, Machine Learning, Triggering Proteins: COVID-19 Updates
Bio-IT World A potential new screening approach, improving immune response to vaccines, new mouse models of SARS-CoV-2, exploring ACE2 receptor activity, a protein that may trigger blood clots, the importance of placenta tissue, hopeful signs that a single vaccine can do the job, and a bioengineering technique to boost production of proteins that prompt antibody development. Plus, machine learning to help identify drug combinations that can be repurposed as potential therapies.
Sep 3, 2020
-
Phil Baran on the Quest to Make Chemistry Boring Again
Bio-IT World | Phil Baran of Scripps Research is dedicated to simplifying chemical synthesis, not to create techniques that are “gimmicky” but will instead become the standard processes of the future. Maybe, “fifty years from now,” he predicts, “we’ll look back in curiosity at chemists of our age who had stages in their syntheses instead of making everything in 1-3 steps.”
Sep 2, 2020
-
Truth Challenge v2: Latest Challenge Results From Genome In A Bottle
Bio-IT World PrecisionFDA and The Genome in a Bottle (GIAB) consortium have announced the results of the Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions such as segmental duplications, and the Major Histocompatibility Complex (MHC).
Sep 2, 2020


